As radiation therapy develops more sophisticated targeting, researchers are turning to new imaging methods to direct it. Fused scintigraphy and CT images and daily ultrasound scanning both show promise as tools to concentrate intensity-modulated radiation therapy (IMRT) and spare surrounding healthy tissue.
As radiation therapy develops more sophisticated targeting, researchers are turning to new imaging methods to direct it. Fused scintigraphy and CT images and daily ultrasound scanning both show promise as tools to concentrate intensity-modulated radiation therapy (IMRT) and spare surrounding healthy tissue.
Researchers at the Mayo Clinic in Scottsdale, AZ, use ProstaScint scans fused with axial CT images of the pelvic region to target hot spots within the prostate. Because the imaging agent is taken up by bone, blood vessels, the bladder, and other anatomic landmarks, coregistration can be closely approximated, according to lead author Dr. Steven Schild.
In 43 patients, Schild and colleagues delivered treatment doses averaging 75.6 Gy over 42 fractions. They set strict limits for how much peripheral radiation exposure would be acceptable in the bladder and rectum.
Among 38 patients followed for six months, only one patient (2%), showed a grade 3 gastrointestinal toxicity. Another 48% showed grade 2 toxicity that could be treated with Imodium. About half had genitourinary symptoms of similar grade. Prostate-specific antigen levels dropped from an average of 6.9 before treatment to 1.9 after.
Researchers in Dijon, France, are using daily ultrasound studies to account for minor shifts in the prostate that could skew IMRT targeting. A software protocol that overlays 3D ultrasound on a simulation-planning CT has been able to track movement of 4 to 6 mm on different axes. The five-minute scan has been incorporated into routine practice since the initial study of 37 patients.
Both techniques underscore an evolution in therapy and targeting, Schild said.
"As we move to more image-guided therapy and to PET and PET/CT for planning, this is an area ripe for future investigation," he said.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Month, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.